Of these proteins, 26 were significantly elevated in the plasma of participants with DS in the HTP cohort, many of which were down-regulated by tofacitinib treatment in this research participant (e.g., CXCL9 and CXCL10; Fig. 6, F and G). The gene discussed is CXCL9; the disease is Dravet syndrome.